CIK 0001875558
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Nuvectis Pharma, Inc.
Sign in to watch- Ticker
- NVCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 862405608
- Phone
- +1 360-837-7232
- Business address
- 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
- 4 Open-market buy Chief Dev. & Ops. Officer bought 404 shares at $8.31 ($3,357)
- 4 Open-market buy Chief Dev. & Ops. Officer bought 3,006 shares at $8.07 ($24,258)
- 4 Open-market buy Chairman & CEO bought 1,500 shares at an average $9.05 ($13,570)
- 4 Open-market buy Chairman & CEO bought 19,426 shares at an average $8.69 ($168,725)
- 4 Open-market buy Chairman & CEO bought 19,669 shares at $8.40 ($165,220)
- 4 Open-market buy Chairman & CEO bought 4,000 shares at an average $11.64 ($46,540)
- 4 Open-market buy Chairman & CEO bought 700 shares at an average $12.09 ($8,462)
- 4 Open-market buy Chairman & CEO bought 1,000 shares at an average $15.82 ($15,820)
- 4 Open-market buy Chairman & CEO bought 1,200 shares at an average $16.73 ($20,070)
- 4 Open-market buy Chief Dev. & Ops. Officer bought 300 shares at $16.54 ($4,962)
- 4 Open-market buy Chairman & CEO bought 2,010 shares at an average $19.48 ($39,155)
- 4 Open-market buy Chief Dev. & Ops. Officer bought 242 shares at an average $19.44 ($4,704)
- 4 Open-market buy Chairman & CEO bought 1,700 shares at an average $18.82 ($31,990)
- 4 Open-market buy Director bought 6,000 shares at $17.40 ($104,400)
- 4 Open-market buy Director bought 3,000 shares at an average $16.88 ($50,633)
- 4 Open-market buy Chief Science & Business Off bought 670 shares at an average $15.33 ($10,273)
- 4 Open-market buy Chief Dev. & Ops. Officer bought 1,278 shares at an average $15.85 ($20,255)
- 4 Open-market buy Chairman & CEO bought 12,245 shares at an average $16.99 ($208,047)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 6 of 7 · 139 filings